HomeCONGRESS

CONGRESS

View Category
Events

Discount for SOLACI Members – V Heart Failure Review 2020

On December 7 thru 12 SOLACI is holding the 5th International Round of Conferences 2020 on “Heart...
solaci -
Learn More
Events

SOCHICAR Pre-Congress: SOLACI/Chile/Uruguay Sessions

Next Wednesday, December 2nd, 2020, at 7:30 p.m. (Chile, Brazil, and Argentina time), there will be an important...
solaci -
Learn More
PHARMACOLOGY

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful...
solaci -
Learn More
Chronic Ischemic cardiopathy

AHA 2020 | Effect of Evolocumab in Complex Coronary Revascularization

Evolocumab, a PCSK9 inhibitor, has shown significant reduction of complex coronary disease requiring revascularization (be it PCI...
solaci -
Learn More
Other

AHA 2020 | Omega-3 Fatty Acids Provide No Cardiovascular Benefits and Cause More Atrial Fibrillation

Results confirm the interim analysis, whereby the study was suspended for futility. Omega-3 fatty acids do not...
solaci -
Learn More
Other

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and...
solaci -
Learn More
Antithrombotic Anticoagulants

AHA 2020 | RIVER: Rivaroxaban as Alternative to Warfarin in Patients with Atrial Fibrillation and Bioprosthetic Mitral Valve

Rivaroxaban seems to be a reasonable alternative to warfarin in patients with atrial fibrillation and bioprosthetic mitral...
solaci -
Learn More
Antiplatelet

AHA 2020 | Clopidogrel Resists as the Best Option in Elective Patients

High risk patients undergoing elective PCI treated with a more potent antiplatelet scheme (ticagrelor) vs. the classic...
solaci -
Learn More